ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Tuesday

Key Points

• ADC Therapeutics is set to announce its Q2 2025 earnings before market opening on August 5th, with anticipated earnings of ($0.36) per share and revenue of $17.82 million.
• The company recently reported Q1 earnings that exceeded expectations, posting ($0.36) EPS against a consensus estimate of ($0.38) and revenue of $23.03 million, which was higher than expected.
• ADC Therapeutics has received multiple analyst ratings, including a "buy" rating from HC Wainwright with a price objective of $8.00, while its current stock price has seen a decline of 4.7%, trading at $3.13.

ADC Therapeutics (NYSE:ADCT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $17.82 million for the quarter.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.02. The firm had revenue of $23.03 million for the quarter, compared to analyst estimates of $17.71 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

Shares of NYSE:ADCT traded down $0.06 during midday trading on Friday, reaching $2.72. 471,179 shares of the company's stock traded hands, compared to its average volume of 577,435. ADC Therapeutics has a 1 year low of $1.05 and a 1 year high of $3.97. The company has a market cap of $269.27 million, a P/E ratio of -1.85 and a beta of 1.89. The company has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $2.08.

Hedge Funds Weigh In On ADC Therapeutics

An institutional investor recently raised its position in ADC Therapeutics stock. AQR Capital Management LLC lifted its stake in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 411.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 201,170 shares of the company's stock after buying an additional 161,808 shares during the quarter. AQR Capital Management LLC owned approximately 0.20% of ADC Therapeutics worth $284,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.10% of the company's stock.

Analyst Upgrades and Downgrades

ADCT has been the subject of a number of recent research reports. Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price (up from $7.00) on shares of ADC Therapeutics in a research note on Friday, June 13th. Royal Bank Of Canada raised ADC Therapeutics from an "outperform" rating to a "moderate buy" rating and cut their target price for the stock from $8.00 to $5.00 in a research note on Friday, June 20th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $7.75.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.